Top Story

SCALE trials: Saxenda promotes weight loss, improves health-related quality of life

May 22, 2015

NASHVILLE, Tenn. - The weight-loss drug Saxenda offers similar benefits across races and was shown to improve health-related quality of life, including physical function and mental health, according to study findings presented here.

In a series of studies analyzing data from the Satiety and Clinical Adiposity - Liraglutide Evidence (SCALE) trials, researchers also demonstrated that adverse gastrointestinal events from Saxenda (liraglutide, Novo Nordisk), including nausea and vomiting, did not affect weight loss.

Meeting News Coverage

High-intensity statin use low in patients with diabetes, high CVD risk

May 22, 2015
NASHVILLE, Tenn. - Patients with type 2 diabetes at very high risk for cardiovascular disease are often not taking high-intensity statins, further increasing their risk…
Meeting News Coverage

Analysis: Most patients prescribed Qsymia as intended

May 22, 2015
NASHVILLE, Tenn. - Adults assigned the weight-loss drug Qsymia are mostly women and white, with a large percentage also taking medications for diabetes and hypertension…
In the Journals

Caffeine consumption reduces risk of erectile dysfunction

May 22, 2015
Men who consumed between 85 mg and 303 mg of caffeine per day were less likely to experience erectile dysfunction, compared with men who consumed less than 7 milligrams…
Priyathama Vellanki Meeting News Coverage

Clinical characteristics, hospital outcomes differ between type 1, type 2 diabetes

May 22, 2015
NASHVILLE, Tenn. - Age-matched patients with type 1 and type 2 diabetes reveal significant differences in inpatient clinical characteristics and hospital outcomes…
More News Headlines »
CME
Obesity Consults: Volume 2, Number 4 Obesity and the Cardiovascular System

Obesity Consults: Volume 2, Number 4
Obesity and the Cardiovascular System

This activity is supported by an educational grant from Eisai, Inc. and Vivus, Inc.

Obesity is associated with a wide range of comorbid conditions, including diabetes, hypertension, sleep apnea, and…
More »
Meeting News Coverage Video
VIDEO: Year in Pituitary Disease examines new developments

VIDEO: Year in Pituitary Disease examines new developments

May 20, 2015
NASHVILLE, Tenn. — In this video exclusive, Mark Molitch, MD, discusses a number of new developments in…
More »
CME
Real-world Use of Anti-VEGF Therapy

Real-world Use of Anti-VEGF Therapy

This activity is supported by an educational grant from Genentech, Inc.

Anti-VEGF is well established as first-line therapy for the treatment of diabetic macular edema (DME) and age-related…
More »
Current Issues
View the Current Issues